Podcasts about Streptococcus

Which bacterium is most strongly associated with starting the dental caries process? A. Lactobacillus B. Streptococcus mutans C. Actinomyces naeslundii D. Bifidobacteria -> Find the answer in the podcast. Here is our WakeUpMemory technique: • S = Start = Streptococcus • L = Late = Lactobacillus • A = Aging roots = Actinomyces • B = Baby caries = Bifidobacteria #1 dental hygiene boards review: 

Estás escuchando #JUNTOSRadio: Cuidando a nuestras familias: prevención e información sobre el sarampión. ¿Qué es y cómo se contagia? ¿Cómo se puede tratar y de qué manera podemos prevenir la enfermedad? Mitos y realidades sobre el sarampión. El Dr. Fernando Merino, Profesor Asistente de Medicina en la División de Enfermedades Infecciosas del Departamento de Medicina del Sistema de Salud de la Universidad de Kansas nos responde estas y otras preguntas. Sobre nuestro invitado: El Dr. Merino obtuvo su título de Médico en la Universidad del País Vasco, en España. Tras graduarse de la Facultad de Medicina, cursó una Maestría en Medicina Tropical en la Universidad de Valencia, también en España. Su formación en Medicina Interna tuvo lugar en el Newton Wellesley Hospital de la Universidad de Tufts, en Massachusetts. Posteriormente, completó su formación de subespecialidad en Enfermedades Infecciosas en la Universidad de Yale, en New Haven, Connecticut. Antes de trasladarse a Kansas en 2007, ejerció su profesión en dos hospitales comunitarios en los estados de Texas y Nueva York. En ambos hospitales se desempeñó como Jefe de Enfermedades Infecciosas y Presidente de los comités de Control de Infecciones y de Optimización del Uso de Antibióticos. El Dr. Merino cuenta con una amplia experiencia clínica, tanto en el tratamiento de infecciones que requieren ingreso hospitalario como en el de aquellas enfermedades que pueden ser manejadas de forma ambulatoria. Sus principales áreas de interés son las infecciones del sistema nervioso central, la infección por VIH, las hepatitis virales, las infecciones en pacientes inmunocomprometidos, las infecciones osteoarticulares, las enfermedades causadas por *Streptococcus pneumoniae* y las enfermedades prevenibles mediante vacunación. Recursos informativos en español CDC información sobre vacunación https://www.cdc.gov/measles/es/vaccines/vacunacion-contra-el-sarampion.html OPS información/ recomendaciones https://es.aft.org/childrens-health/mental-health/eating-disorders Facebook: @juntosKS Instagram: juntos_ks YouTube: Juntos KS Página web: http://juntosks.org Suscríbete en cualquiera de nuestras plataformas de Podcast: Podbean, Spotify, Amazon Music y Apple Podcast - Juntos Radio Centro JUNTOS 4125 Rainbow Blvd. M.S. 1076, Kansas City, KS 66160 Este programa es únicamente con fines educativos. Para recibir un diagnóstico o tratamiento, consulte a su médico. La información proporcionada por el invitado es responsabilidad de este. No tenemos los derechos de autor de la música que aparece en este video. Todos los derechos de la música pertenecen a sus respectivos creadores.

Group A Streptococcal infections remain a global challenge, spanning common conditions like pharyngitis to severe invasive disease. Dr. Shiranee Sriskandan, Dr. Josh Osowicki, and Dr. Tom Parks join host Dr. Erin McCreary to explore the evolving landscape of Group A Strep. From unpacking vaccine development challenges and the ongoing burden of rheumatic fever, to rethinking durations of therapy for strep throat and the role of adjunctive treatments, we have you covered! Join us as we break down key controversies, share expert insights, and highlight practical pearls you can apply in your own practice. References: 1. https://www.lancefieldsociety.org/ 2. Osowicki J, Lamagni TL. Invasive Group A Streptococcal Disease in the US. JAMA. 2025;333(17):1493-1494. doi:10.1001/jama.2025.3257 3. Davis K, Abo YN, Steer AC, Osowicki J. Chains of misery: surging invasive group A streptococcal disease. Curr Opin Infect Dis. 2024;37(6):485-493. doi:10.1097/QCO.0000000000001064 4. Osowicki J, Azzopardi KI, Fabri L, et al. A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study. Lancet Microbe. 2021;2(7):e291-e299. doi:10.1016/S2666-5247(20)30240-8 5. Hla TK, Osowicki J, Marsh JA, et al. Establishing the lowest penicillin concentration to prevent pharyngitis due to Streptococcus pyogenes using a human challenge model (CHIPS): a randomised, double-blind, placebo-controlled trial. Lancet Microbe. 2025;6(5):101038. doi:10.1016/j.lanmic.2024.101038 Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/)https://www.instagram.com/breakpointspodcast_sidp/?hl=en Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Antimicrobial resistance (AMR) is being called the "silent pandemic" by global health experts, but what does that actually mean? In this episode of the Wholistic Living Podcast, we explore why antibiotic-resistant infections are increasing worldwide, how bacteria develop resistance through biofilms and horizontal gene transfer, and why common microbes such as E. coli, Klebsiella, Streptococcus, and Enterococcus are becoming a growing concern. Learn why most colds and flus are viral and do not respond to antibiotics, how repeated antibiotic use can impact the gut microbiome, and what a holistic approach to immune resilience can teach us about preventing infection. We'll discuss the latest antimicrobial resistance statistics, the role of stool testing, and practical ways to support your immune system naturally through nutrition, lifestyle, and gut health.Equip Grass fed protein: www.equipfoods.com/MARLA60 Day Gut Reset ($200 OFF) - https://checkout.teachable.com/secure/1716725/checkout/order_52y48hdz?coupon_code=SECRETOFFER

TWiM explains how Streptococcus mitis bacteriocins drive contact-dependent lysis of S. pneumoniae facilitating transformation, and microbial dominance in diabetic foot osteomyelitis determined with nanopore sequencing. Hosts: Vincent Racaniello, Michael Schmidt, and Michele Swanson Subscribe to TWiM (free) on Apple Podcasts, Stitcher, RSS, or by email. Links for this episode Streptococcus mitis bacteriocins drive contact-dependent lysis of S. pneumoniae (mBio) Microbial dominance in diabetic foot osteomyelitis determined with nanopore sequencing (J Inf Dis) Diabetic foot ulcer review (World J Clin Cases) How nanopore sequencing works (YouTube) Become a Patron of TWiM! Music used on TWiM is by Ronald Jenkees. Send your microbiology questions and comments to twim@microbe.tv

Told donor eggs after failed IVF? There is a category of testing that your fertility clinic does not run. We rarely run a stool test and find nothing. The IVF cycle did not work. Maybe it was poor response. Maybe it was canceled before retrieval. Maybe you got embryos and they arrested. Maybe the transfer failed. Your clinic looked at your numbers and told you donor eggs. In this episode, Sarah Clark walks through the gut pattern the Fab Fertile team sees in women who come to us after failed IVF with a donor egg recommendation, and why this pattern changes the picture before the next decision. What this episode covers: H. pylori. One of the most common findings in the women who come to us after failed IVF. It impairs absorption of iron, vitamin B12, and zinc, the nutrients that affect egg quality, thyroid function, and hormone production. It is passed back and forth between partners through saliva. If you have it, there is a strong chance your partner has it too. Parasites, giardia, blastocystis. Common findings. Rarely tested at the fertility clinic. Bacterial overgrowth, including streptococcus. Fungal overgrowth and dysbiosis. The reason chasing an anti-candida diet without testing moves you in circles. Elevated calprotectin. A signal of gut inflammation, often present in women with IBD, Crohn's, colitis, and women with no formal diagnosis. Elevated zonulin. A marker of intestinal permeability. The pattern we see after rounds of antibiotics, sinus infections, UTIs, birth control, and high stress. Why this matters before a donor egg decision: H. pylori impairs iron absorption. Ferritin reads low or low-normal. The clinic says iron is fine because the lab range starts around 15. The fertility-optimized range is closer to 50. Iron is foundational to egg quality. The oxygen carrying capacity to your follicles depends on it. B12 affects methylation, the process your body uses to produce the co-factors needed for egg maturation. Zinc affects ovulation and progesterone production. Chronic gut inflammation affects ovarian response to stimulation, implantation, and miscarriage risk. When your clinic looks at a canceled cycle, arrested embryos, or a failed transfer and recommends donor eggs, they are responding to the outcome. They are not asking what is driving the outcome. This episode is for the woman sitting with a donor egg recommendation who is not ready to agree before she understands what was actually evaluated. Next steps: Access the free guide: What Your Clinic Missed. It walks through the markers we review before a donor egg recommendation, including the thyroid panel, the iron panel with the fertility target, the gut testing your REI does not order, the inflammatory markers, and the male side. Email hello@fabfertile.ca, subject line MISSED. Book a Functional Fertility Second Opinion. We will review your labs, your history, your full picture, and your partner's picture together. You will leave knowing what your biology has been telling you and what your next decision should be informed by. Email hello@fabfertile.ca, subject line FERTILE. Or apply here. About the Host I'm Sarah Clark, founder of Fab Fertile and host of Get Pregnant Naturally, a podcast with over one million downloads. My functional fertility team works with couples navigating low AMH and failed IVF, reviewing functional lab results, gut microbiome, food sensitivity, vaginal microbiome, nutrigenomics, HTMA, DUTCH, toxin testing, and  bloodwork alongside nervous system work, to help identify patterns that may not have been considered. We work alongside your medical team, not instead of them. Subscribe to Get Pregnant Naturally for weekly episodes on fertility optimization, IVF preparation, and the lab work your doctor probably isn't running. Timestamps [00:00] Told Donor Eggs After Failed IVF [01:00] Why the Fab Fertile Team Reviews Your Picture [02:00] H. pylori: The Most Common Gut Finding We See [03:00] Parasites, Streptococcus, and the Bacteria Most REIs Do Not Test [04:00] Why a Single Gut Test Without Fertility Context Misses the Picture [05:00] Iron, Ferritin, and the Fertility Range vs the Lab Range [06:00] B12, Methylation, and Egg Maturation [07:00] Zinc, Ovulation, and Progesterone [08:00] What Your Clinic Missed: The Markers Before a Donor Egg Recommendation [09:00] Why a Donor Egg Recommendation Responds to the Outcome, Not the Cause [10:00] The Functional Fertility Second Opinion: What the Call Covers

Vincent travels to Oregon State University in Corvallis to meet up with Hannah Rowe to talk about her career and her work demonstrating how the interaction of influenza A virus and Streptococcus pneumonia influences transmission. Hosts: Vincent Racaniello Guest: Hannah Rowe Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Positions in Rosenfeld Lab (email) Respiratory bacteria stabilize influenza A virus (mSystems) S. pneumoniae and influenza A virus binding (mSphere) Bacterial alteration of redox stressors and stability of influenza A virus (mSphere) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of exciting advancements and strategic moves that are shaping the future of healthcare. Let's start with Pfizer's efforts in pneumococcal vaccination, a testament to the ongoing battle against Streptococcus pneumoniae. With their sights set on expanding protection and combating emerging health threats, Pfizer's initiatives reflect an industry-wide commitment to adapt to microbial challenges, potentially enhancing global public health outcomes. Their work underscores the crucial role vaccines play in preventing severe infections and maintaining public health. In other news, Parabilis Medicines is making strides by eyeing public markets to bolster its phase 3 tumor drug development. This move highlights the increasing reliance on public funding to advance late-stage clinical trials, which are essential for bringing new therapies to patients. Meanwhile, Lilly's acquisition of Engage for $202 million marks a significant expansion into non-viral DNA delivery systems. These systems could address traditional gene therapy challenges, promising more effective and safer genetic medicine options. Immunovant recently decided to discontinue its first-generation FcRn inhibitor after disappointing phase 3 results. This decision illustrates the unpredictable nature of drug development, where clinical evaluations often lead companies to reassess strategies based on trial outcomes. Such pivots are part and parcel of the rigorous scientific process that drives innovation forward. The integration of artificial intelligence in drug discovery is gaining momentum. Incyte's $80 million investment to expand its AI-driven partnership with Genesis is a clear indication of AI's growing importance in optimizing drug discovery. Similarly, Bristol Myers Squibb's collaboration with Anthropics Claude highlights a broader trend of leveraging AI across R&D processes to enhance efficiency and streamline operations. Additionally, Incyte's partnership with Edison Scientific to integrate Kosmos AI across R&D workflows exemplifies AI and machine learning's growing role in enhancing oncology drug discovery processes. Enter Oorja Bio, a newcomer focusing on idiopathic pulmonary fibrosis with a $30 million launch fund. Their novel approach to tackling this debilitating condition exemplifies the innovative spirit within smaller biotech firms aiming to address unmet medical needs. Oorja Bio's efforts are part of a larger movement in biotech where new entrants are making significant impacts by targeting specific diseases with fresh perspectives. On the regulatory front, Gilead has expanded its partnership with Korean manufacturer Yuhan through a $140 million deal for active pharmaceutical ingredients. This strategic move ensures robust supply chains amid evolving regulatory standards and market demands, underscoring the importance of global partnerships in maintaining drug availability and quality. Turning our attention to oncology, the American Society of Clinical Oncology (ASCO) 2026 conference is poised to be a significant event for industry professionals. The focus this year includes precision oncology and evolving trial designs, particularly for pancreatic cancer. The complexity of oncology studies demands tailored solutions for efficacy and regulatory compliance, pushing toward more adaptive and patient-centric trial designs. City of Hope's participation at ASCO emphasizes collaborative efforts in cancer research, combining cutting-edge science with comprehensive patient care to translate breakthroughs into tangible improvements in outcomes. Labcorp's involvement further underscores precision oncology's role through biomarker-driven trials and companion diagnostic development. The conversation at ASCO 2026 will also explore the future design of pancreatic cancer trials. By incorporating external controls and real-world data, researchers aim to streamline processes and expedite access to new therapies, acknowledging pancreatic cancer's unique challenges. In other significant advancements, UCB's Bimzelx showed superior efficacy over Skyrizi in treating psoriatic arthritis during a Phase 3 trial. As an IL-17A/IL-17F inhibitor, Bimzelx represents a promising biologic therapy option, potentially setting new standards in autoimmune treatment. Roche's voluntary license agreement with Medicines Patent Pool for Xofluza accessibility highlights efforts towards global health equity, ensuring essential medications reach low- and middle-income countries. Finally, financial movements such as Mentari Therapeutics' reverse merger raise substantial capital for neurological therapies, exemplifying ongoing investment confidence within the sector. These stories collectively illustrate an era marked by scientific innovation, strategic partnerships, and technological integration aimed at improving patient care and accelerating drug development pathways. As we continue to explore these advancements on Pharma Daily, stay tuned for more insights into how these developments shape our industry's future. That's all for today's episode of Pharma Daily. Thank you for tuning in as we navigate through these transformative times in pharmaceuticals and biotechnology.Support the show

While the gut microbiome often steals the spotlight, the microorganisms residing in our respiratory tract play a vital role in our health and immunity. In this episode, Dr. Sheena Fraser sits down with microbial ecologist Dr. Michael Cox to explore the fascinating, complex, and relatively uncharted territory of the lung microbiome.They discuss how the lung microbiome fundamentally differs from the gut, the daily flux of bacteria entering and leaving our airways, and the profound impacts of environmental factors like air pollution, smoking, vaping, and household cleaning products. Plus, Dr. Cox shares the massive challenges scientists face when studying these deep-tissue microbes and what the future of respiratory medicine might look like.What We Cover:From Seawater to Sputum: Using marine ecology techniques to decode human respiratory biology.Exploring the lungs' dynamic balance of microaspiration and mucociliary clearance.Meet the core lung bacteria (Streptococcus, Prevotella, Veillonella) and the puzzle of anaerobes in an oxygen-rich space.Environmental Disruptors: How pollution, smoking, and vaping inflame and alter the lung microbiome.Hidden Dangers of VOCs: The silent impact of everyday cleaning sprays and aerosols on respiratory health.Diet, Exercise, & Epigenetics: The systemic benefits of a high-fiber diet and fitness for chronic lung conditions like COPD and asthma.About Dr. Michael Cox is a microbial ecologist and the PGR Lead for the Institute of Microbiology and Infection at the University of Birmingham. His research focuses on the bacteria that reside in the respiratory tract in the context of respiratory diseases (such as COPD and Cystic Fibrosis). His lab works to understand the function of the respiratory microbiome, translate these findings for clinical benefit, and expand our understanding of the respiratory ecosystem beyond just bacteria.Connect with Dr Michael Cox:University of BirminghamScientific References & Further Reading:Cumming, K. J. (2018). "Long term effects of cleaning on the lungs." American Journal of Respiratory and Critical Care Medicine, 197(9):1099-1101.Hussain, S., et al. (2024). "Unlocking the secrets: VOCs and their devastating effects on lung cancer." Pathology - Research and Practice, 255:155157.Welsh, H. A., et al. (2026). "The effect of vaping on the human lung microbiota." Inhalation Toxicology, Vol 38, Iss 1.This podcast is brought to you in collaboration with the British Society of Lifestyle Medicine.Disclaimer:The content in this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare provider. Never disregard professional medical advice or delay in seeking it because of something you have heard on this podcast.

Genelde "Et Yiyen Bakteri" olarak bilinen "A Streptococcus" bakteri sınıfı sebebiyle ortaya çıkan ve bağ dokusunun doku ölümüne sebep olan iltihabı olarak tanımlanan bu hastalık nedir?

Why has yogurt making gone viral?First of all, it's NOT yogurt. It looks and smells like yogurt. By FDA regulations, something called yogurt must be fermented with traditional yogurt-making microbes Lactobacillus bulgaricus and Streptococcus thermophilus. That's NOT what we are doing. Instead, we are fermenting human microbes, i.e., microbes that are adapted to the human body and provide substantial benefits but have been lost by most people because of their susceptibility to common antibiotics. Using my methods (prolonged fermentation, addition of prebiotic fiber, selecting microbial species to achieve specific effects) we obtain hundreds of billions of microbes per serving for greater benefits. These are the concepts I introduced in my Super Gut book and extended further in the Super Body book. Support the showYouTube channel: https://www.youtube.com/@WilliamDavisMD Blog: WilliamDavisMD.com Membership website for two-way Zoom group meetings: InnerCircle.DrDavisInfiniteHealth.com Books: Super Gut: The 4-Week Plan to Reprogram Your Microbiome, Restore Health, and Lose Weight Wheat Belly: Lose the Wheat, Lose the Weight and Find Your Path Back to Health; revised & expanded ed

Do you wake up in the morning with a runny rose constantly? Have you been struggling with this a long time? Maybe you are struggling with strep throat? In today's episode of Happiness From Within we dive deep into the root cuase of strep through the Medical Medium protocols. It will help you get to the root cuase of Streptococcus through the Medical Medium protocols.   More Great Episodes for Healing https://youtu.be/6SJAPvdaK4U?si=q53EVtTknbRss8_x Apply to Become A Sponsor of Happiness From Within https://forms.gle/AiF5MFGtzyGRKZLB9   By accessing this Podcast, I acknowledge that the entire contents are the property of Happiness From Within, or used by Happiness From Within with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this Podcast may save and use information contained in the Podcast only for personal or other non-commercial, educational purposes. No other use, including, without limitation, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of the Happiness From Within, which may be requested by contacting info@happinessfromwithinow.com This podcast is for educational purposes only. The host claims no responsibility to any person or entity for any liability, loss, or damage caused or alleged to be caused directly or indirectly as a result of the use, application, or interpretation of the information presented herein. The information provided on this Site is for general informational purposes only, and any linked material. The information is not intended to be a substitute for professional health or medical advice or treatment, nor should it be relied upon for the diagnosis, prevention, or treatment of any health consideration. Consult with a licensed health care practitioner before altering or discontinuing any medications, treatment or care, or starting any diet, exercise or supplementation program. Neither Janet Prado nor Happiness From Withinis a licensed medical doctor or other formally licensed health care practitioner or provider. The content of this podcast and any linked material does not necessarily reflect the opinions of Happiness From Within or the principal author, and is not guaranteed to be correct, complete, or up to date.

The Interdisciplinary Meeting of Antimicrobial Resistance and Innovation has launched! The first version of IMARI brought together researchers, clinicians, industry leaders and policymakers to address one of the greatest challenges in modern medicine: antimicrobial resistance" Check the highlights at IMARI.org and prepare for IMARI 2017 from January 27-29, 2027! The inaugural amazing conference took place in Las Vegas. This is the forst time that ASM and IDSA collaborate together in a scientific meeting. One of the sessions involved an unprecedent collaboration between two journals AAC and JID published by each society. To celebrate this achievement we had a session of the best AMR papers of 2025 for AAC and JID. This session will be presented here as apart of our series.  Watch this episode: https://youtu.be/XRYl7863z34 Objectives: - Review the best papers and topics of AMR in 2025 form AAC and JID. - Discuss the context of each finding and contributions to the AMR community - Elaborate on the implications for AMR, novelties and how the field is advancing. Guests:  - Ayesha Khan, Ph.D.  Assistant Professor, Pathology & Laboratory Medicine and Associate Director, Division of Clinical Microbiology Biomedical & Translational Research Track. Principal Investigator, UC3P UCI Prime Pre-Health Pathways Program. - Madison Stellfox, M.D. Ph.D. Assistant Professor of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.  Links:  Links: AAC A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp. https://doi.org/10.1128/aac.01627-24 JID Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model https://doi.org/10.1093/infdis/jiaf567 AAC Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors https://doi.org/10.1128/aac.01614-24 JID Daptomycin-Loaded Nanocarriers Facilitate Synergistic Killing of Methicillin-Resistant Staphylococcus aureus via Lipid-Mediated Interactions and Targeting https://doi.org/10.1093/infdis/jiaf492 AAC Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact https://doi.org/10.1128/aac.00237-25 JID Blood Cultures Contain Populations of Genetically Diverse Candida albicans Strains that May Differ in Echinocandin Tolerance and Fitness https://doi.org/10.1093/infdis/jiaf495 AAC Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains https://doi.org/10.1128/aac.00137-25 JID Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates https://doi.org/10.1093/infdis/jiae438 AAC Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice https://doi.org/10.1128/aac.01310-24 JID The Changing Paradigm in Infectious Diseases—Host-Directed Medicine: Implications for the Next Generation of ID Physicians https://doi.org/10.1093/infdis/jiaf497 JID Triggering Toll-Like Receptor 5 Signaling During Pneumococcal Superinfection Prevents the Selection of Antibiotic Resistance https://doi.org/10.1093/infdis/jiae239 IMARI Conference This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at https://asm.org/aac.  If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit https://asm.org/joinasm to sign up. Visit https://asm.org/aac to browse issues and/or submit a manuscript. Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates. 

We review diagnosing and managing bacterial meningitis in the ED. Hosts: Sarah Fetterolf, MD Avir Mitra, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Meningitis_2_0.mp3 Download Leave a Comment Tags: CNS Infections, Infectious Diseases, Neurology Show Notes Core EM Modular CME Course Maximize your commute with the new Core EM Modular CME Course, featuring the most essential content distilled from our top-rated podcast episodes. This course offers 12 audio-based modules packed with pearls! Information and link below.  Course Highlights: Credit: 12.5 AMA PRA Category 1 Credits™ Curriculum: Comprehensive coverage of Core Emergency Medicine,  with 12 modules spanning from Critical Care to Pediatrics. Cost: Free for NYU Learners $250 for Non-NYU Learners Click Here to Register and Begin Module 1 Patient Presentation & Workup Patient: 36-year-old male, currently shelter-domiciled, presenting with 3 weeks of generalized weakness, fevers, weight loss, and headaches. Vitals (Initial): BP 147/98, HR 150s, Temp 100.2°F, RR 18, O2 99% RA. Clinical Evolution: Initial assessment noted cachexia and a large ventral hernia. Following initial workup, the patient became acutely altered (A&O x0) and febrile to 102.9°F. Physical Exam Findings: Brudzinski Sign: Positive (knees flexed upward upon passive neck flexion). Kernig Sign: Discussed as highly specific (resistance/pain during knee extension with hip flexed at 90°). Meningeal Triad: Fever, nuchal rigidity, and AMS (present in 40% of cases; 95% of patients have at least two of the four cardinal symptoms including headache). Imaging: Chest X-ray: Scattered opacities (pneumonia) and a small pneumothorax. CT Abdomen/Pelvis: Confirmed asplenia (secondary to 2011 GSW/exploratory laparotomy). Head CT: Ventricle enlargement concerning for obstructive hydrocephalus and diffuse sulcal effacement. CSF Analysis & Microbiology Bacterial Meningitis Opening Pressure: Elevated (Normal is 1000–2000/mm3 WBC); dominated by neutrophils (>80% PMN). Glucose: Low (

Drs. Ted Morton and Christine Lockowitz join Dr. Ryan Moenster to discuss all things amoxicillin, particularly in our pediatric patients. Our guests answer common questions, such as, what formulations should be used for certain infectious conditions and/or organisms and how to dose amoxicillin to maximize PK/PD optimization without inducing potential adverse events. It is a must-listen for all! This episode also qualifies for 1 hour of BCIDP credit! How to Obtain BCIDP Recertification Credit for this Episode: Visit sidp.org/BCIDP for more information. References: Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J. 2010 Nov;29(11):1043-6. doi: 10.1097/INF.0b013e3181f42a53. PMID: 20975453. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2. doi: 10.1086/516284. PMID: 9455502. Hakenbeck R, Grebe T, Zähner D, Stock JB. beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol Microbiol. 1999 Aug;33(4):673-8. doi: 10.1046/j.1365-2958.1999.01521.x. PMID: 10447877. Bax R. Development of a twice daily dosing regimen of amoxicillin/clavulanate. Int J Antimicrob Agents. 2007 Dec;30 Suppl 2:S118-21. doi: 10.1016/j.ijantimicag.2007.09.002. Epub 2007 Nov 5. PMID: 17983732. Bielicki JA, Stöhr W, Barratt S, Dunn D, Naufal N, Roland D, Sturgeon K, Finn A, Rodriguez-Ruiz JP, Malhotra-Kumar S, Powell C, Faust SN, Alcock AE, Hall D, Robinson G, Hawcutt DB, Lyttle MD, Gibb DM, Sharland M; PERUKI, GAPRUKI, and the CAP-IT Trial Group. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1713-1724. doi: 10.1001/jama.2021.17843. Erratum in: JAMA. 2021 Dec 7;326(21):2208. doi: 10.1001/jama.2021.20219. PMID: 34726708; PMCID: PMC8564579.

The Vaccine Group (TVG) CEO Jeremy Salt talked with Proactive's Stephen Gunnion about encouraging efficacy results for the company's Streptococcus suis vaccine candidate, marking an important step forward for its veterinary vaccine platform. TVG is a Frontier IP Group PLC (LSE:FIPP, FRA:8WT) portfolio company. Salt explained that the latest results demonstrate how effective the vaccine candidate can be against Streptococcus suis, a serious bacterial disease affecting pigs globally. He said the findings are particularly significant as they show the strength and flexibility of the company's platform technology across multiple disease types. “It's a very nice indication of how effective this vaccine candidate can be against this particular disease,” Salt noted. Streptococcus suis is widely distributed in commercially farmed pigs, with hundreds of millions of animals potentially affected worldwide. Salt highlighted that the disease is a major contributor to antibiotic use in pig farming and that a successful vaccine could help significantly reduce reliance on antibiotics. He also pointed out the zoonotic nature of the disease, which can infect humans who work with pigs or handle pork products, sometimes with severe or fatal outcomes. TVG has already demonstrated the efficacy of its platform against viral disease, including bovine respiratory syncytial virus in cattle, and Salt said the latest pig data further underlines the breadth of the technology. The company is currently engaged in discussions with a commercial partner and aims to move the Streptococcus suis vaccine into a full development phase. Salt added that TVG is also seeking partners for its cattle vaccine and intends to use future funding to advance a broader portfolio spanning livestock and companion animals. Visit Proactive's YouTube channel for more videos, and don't forget to like this video, subscribe to the channel, and enable notifications for future updates. #TheVaccineGroup #StreptococcusSuis #VeterinaryVaccines #AnimalHealth #PigFarming #LivestockHealth #VaccineDevelopment #AntibioticReduction #ZoonoticDisease #ProactiveInvestors

A 2026 narrative review published in Nutrients investigated how A1 and A2 beta-casein variants specifically impact the human and murine gut environment. While cow's milk is a dietary staple, the A1 variant—common in Northern European breeds—differs from the ancestral A2 variant by a single amino acid mutation that allows for the release of beta-casomorphin-7 (BCM-7) during digestion.This review of eight recent studies found that A1 beta-casein is more frequently associated with dysbiosis and an increased abundance of potentially pathogenic species like Streptococcus pyogenes. Conversely, A2 beta-casein was shown to promote greater microbial diversity and significantly increase beneficial taxa, including Lactobacillus animalis and Bifidobacterium longum. In specific models, A2 consumption led to a significant increase in short-chain fatty acids (SCFAs) like acetate and butyrate, which are critical for gut integrity and metabolic health. These findings suggest that for individuals experiencing digestive discomfort, choosing A2-dominant dairy may offer a more favorable gut environment and reduced inflammation compared to traditional A1 milk.Disclaimers• This information is for educational purposes only and should not be interpreted as medical advice. • The majority of the studies reviewed (7 out of 8) utilized murine models. Further well-designed human clinical trials are necessary to confirm these effects in broader populations. • Always consult with a qualified healthcare professional before making significant changes to your diet, especially if you have diagnosed digestive conditions or milk allergies.#A2Milk #GutHealth #Microbiome #NutritionScience #DigestiveHealth #Casein #LactoseIntolerance #Probiotics #HealthyLiving #DairyScience #Microbiota #Inflammation #BioactivePeptides #Bifidobacterium #GutBrainAxisAMA CitationSujani S, Czerwinski KJ, Savaiano DA. A Narrative Review: A1 and A2 Milk Beta Caseins Effect on Gut Microbiota. Nutrients. 2026;18(1):138. doi:10.3390/nu18010138.Alchepharma,Ralph Turchiano,citation,research,study,A1 vs A2 milk gut microbiota,beta-casomorphin-7 health effects,A2 milk benefits for bloating,milk protein variants and dysbiosis,Bifidobacterium longum and dairy,dairy-induced gut inflammation,milk casein mutation history,Purdue University nutrition research 2026,short chain fatty acids milk digestion,A2 milk metabolic health,gut-microbiota-brain axis dairy,A2 milk for sensitive stomachs,cow breeds A1 vs A2 protein

Osteomyelitis in children is common enough to miss and serious enough to matter. In this episode of PEM Currents, we review a practical, evidence-based approach to pediatric acute hematogenous osteomyelitis, focusing on diagnostic strategy, imaging decisions including FAST MRI, and modern antibiotic management. Topics include age-based microbiology, empiric and pathogen-directed antibiotic selection with dosing, criteria for early transition to oral therapy, and indications for orthopedic and infectious diseases consultation. Special considerations such as MRSA, Kingella kingae, daycare clustering, and shortened treatment durations are discussed with an emphasis on safe, high-value care. Learning Objectives After listening to this episode, learners will be able to: Identify the key clinical, laboratory, and imaging findings that support the diagnosis of acute hematogenous osteomyelitis in children, including indications for FAST MRI and contrast-enhanced MRI. Select and dose appropriate empiric and pathogen-directed antibiotic regimens for pediatric osteomyelitis based on patient age, illness severity, and local MRSA prevalence, and determine when early transition to oral therapy is appropriate. Determine when consultation with orthopedics and infectious diseases is indicated, and recognize clinical features that warrant prolonged therapy or more conservative management. References Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. J Pediatric Infect Dis Soc. 2021;10(8):801-844. doi:10.1093/jpids/piab027 Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2023 guideline on diagnosis and management of acute bacterial arthritis in pediatrics. J Pediatric Infect Dis Soc. 2024;13(1):1-59. doi:10.1093/jpids/piad089 Stephan AM, Platt S, Levine DA, et al. A novel risk score to guide the evaluation of acute hematogenous osteomyelitis in children. Pediatrics. 2024;153(1):e2023063153. doi:10.1542/peds.2023-063153 Alhinai Z, Elahi M, Park S, et al. Prediction of adverse outcomes in pediatric acute hematogenous osteomyelitis. Clin Infect Dis. 2020;71(9):e454-e464. doi:10.1093/cid/ciaa211 Burns JD, Upasani VV, Bastrom TP, et al. Age and C-reactive protein associated with improved tissue pathogen identification in children with blood culture-negative osteomyelitis: results from the CORTICES multicenter database. J Pediatr Orthop. 2023;43(8):e603-e607. doi:10.1097/BPO.0000000000002448 Peltola H, Pääkkönen M. Acute osteomyelitis in children. N Engl J Med. 2014;370(4):352-360. doi:10.1056/NEJMra1213956 Transcript This transcript was provided via use of the Descript AI application Welcome to PEM Currents, the Pediatric Emergency Medicine Podcast. As always, I'm your host, Brad Sobolewski, and today we're covering osteomyelitis in children. We're going to talk about diagnosis and imaging, and then spend most of our time where practice variation still exists: antibiotic selection, dosing, duration, and the evidence supporting early transition to oral therapy. We'll also talk about when to involve orthopedics, infectious diseases, and whether daycare outbreaks of osteomyelitis are actually a thing. So what do I mean by pediatric osteomyelitis? In children, osteomyelitis is most commonly acute hematogenous osteomyelitis. That means bacteria seed the bone via the bloodstream. The metaphysis of long bones is particularly vulnerable due to vascular anatomy that favors bacterial deposition. Age matters. In neonates, transphyseal vessels allow infection to cross into joints, increasing the risk of concomitant septic arthritis. In older children, those vessels involute, and infection tends to remain metaphyseal and confined to bone rather than spreading into the joint. For children three months of age and older, empiric therapy must primarily cover Staphylococcus aureus, which remains the dominant pathogen. Other common organisms include group A streptococcus and Streptococcus pneumoniae. In children six to 36 months of age, especially those in daycare, Kingella kingae is an important and often underrecognized pathogen. Kingella infections are typically milder, may present with lower inflammatory markers, and frequently yield negative routine cultures. Kingella is usually susceptible to beta-lactams like cefazolin, but is consistently resistant to vancomycin and often resistant to clindamycin and antistaphylococcal penicillins. This has direct implications for empiric antibiotic selection. Common clinical features of osteomyelitis include fever, localized bone pain, refusal to bear weight, and pain with movement of an adjacent joint. Fever may be absent early, particularly with less virulent organisms like Kingella. A normal white blood cell count does not exclude osteomyelitis. Only about one-third of children present with leukocytosis. CRP and ESR are generally more useful, particularly CRP for monitoring response to therapy. No single CRP cutoff reliably diagnoses or excludes osteomyelitis in children. While CRP is elevated in most cases of acute hematogenous osteomyelitis, the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America note that high-quality data defining diagnostic thresholds are limited. A CRP above 20 milligrams per liter is commonly used to support clinical suspicion, with pooled sensitivity estimates around 80 to 85 percent, but no definitive value mandates the diagnosis. Lower values do not exclude disease, particularly in young children, as CRP is normal in up to 40 percent of Kingella kingae infections. CRP values tend to be higher in Staphylococcus aureus infections, especially MRSA, and higher levels are associated with complications such as abscess, bacteremia, and thrombosis, though specific cutoffs are not absolute. In summary, CRP is most useful for monitoring treatment response. It typically peaks two to four days after therapy initiation and declines rapidly with effective treatment, with a 50 percent reduction within four days seen in the majority of uncomplicated cases. Blood cultures should be obtained in all children with suspected osteomyelitis, ideally before starting antibiotics when feasible. In children, blood cultures alone can sometimes identify the pathogen. Plain radiographs are still recommended early, not because they're sensitive for acute osteomyelitis, but because they help exclude fracture, malignancy, or foreign body and establish a baseline. MRI with and without contrast is the preferred advanced imaging modality. MRI confirms the diagnosis, defines the extent of disease, and identifies complications such as subperiosteal abscess, physeal involvement, and concomitant septic arthritis. MRI findings can also guide the need for surgical consultation. Many pediatric centers now use FAST MRI protocols for suspected osteomyelitis, particularly from the emergency department. FAST MRI uses a limited sequence set, typically fluid-sensitive sequences like STIR or T2 with fat suppression, without contrast. These studies significantly reduce scan time, often avoid the need for sedation, and retain high sensitivity for bone marrow edema and soft tissue inflammation. FAST MRI is particularly useful when the clinical question is binary: is there osteomyelitis or not? It's most appropriate in stable children without high concern for abscess, multifocal disease, or surgical complications. If FAST MRI is positive, a full contrast-enhanced MRI may still be needed to delineate abscesses, growth plate involvement, or adjacent septic arthritis. If FAST MRI is negative but clinical suspicion remains high, further imaging may still be necessary. The Pediatric Infectious Diseases Society and the Infectious Diseases Society of America recommend empiric antibiotic selection based on regional MRSA prevalence, patient age, and illness severity, with definitive therapy guided by culture results and susceptibilities. Empiric therapy should never be delayed in an ill-appearing or septic child. In well-appearing, stable children, antibiotics may be briefly delayed to obtain imaging or tissue sampling, but this requires close inpatient observation. For children three months and older with non–life-threatening disease, empiric therapy hinges on local MRSA rates. In regions with low community-acquired MRSA prevalence, generally under 10 percent, reasonable empiric options include cefazolin, oxacillin, or nafcillin. When MRSA prevalence exceeds 10 to 20 percent, empiric therapy should include an MRSA-active agent. Clindamycin is appropriate when local resistance rates are low, while vancomycin is preferred when clindamycin resistance is common or the child has had significant healthcare exposure. For children with severe disease or sepsis, vancomycin is generally preferred regardless of local MRSA prevalence. Some experts recommend combining vancomycin with oxacillin or nafcillin to ensure optimal coverage for MSSA, group A streptococcus, and MRSA. In toxin-mediated or high-inoculum infections, the addition of clindamycin may be beneficial due to protein synthesis inhibition. Typical IV dosing includes cefazolin 100 to 150 milligrams per kilogram per day divided every eight hours; oxacillin or nafcillin 150 to 200 milligrams per kilogram per day divided every six hours; clindamycin 30 to 40 milligrams per kilogram per day divided every six to eight hours; and vancomycin 15 milligrams per kilogram every six hours for serious infections, with appropriate monitoring. Ceftaroline or daptomycin may be considered in select MRSA cases when first-line agents are unsuitable. For methicillin-susceptible Staphylococcus aureus, first-generation cephalosporins or antistaphylococcal penicillins remain the preferred parenteral agents. For oral therapy, high-dose cephalexin, 75 to 100 milligrams per kilogram per day divided every six hours, is preferred. Clindamycin is an alternative when beta-lactams cannot be used. For clindamycin-susceptible MRSA, clindamycin is the preferred IV and oral agent due to excellent bioavailability and bone penetration, and it avoids the renal toxicity associated with vancomycin. For clindamycin-resistant MRSA, vancomycin or ceftaroline are preferred IV agents. Oral options are limited, and linezolid is generally the preferred oral agent when transition is possible. Daptomycin may be used parenterally in children older than one year without pulmonary involvement, typically with infectious diseases and pharmacy input. Beta-lactams remain the drugs of choice for Kingella kingae, Streptococcus pyogenes, and Streptococcus pneumoniae. Vancomycin has no activity against Kingella, and clindamycin is often ineffective. For Salmonella osteomyelitis, typically seen in children with sickle cell disease, third-generation cephalosporins or fluoroquinolones are used. In underimmunized children under four years, consider Haemophilus influenzae type b, with therapy guided by beta-lactamase production. Doxycycline has not been prospectively studied in pediatric acute hematogenous osteomyelitis. There are theoretical concerns about reduced activity in infected bone and risks related to prolonged therapy. While short courses are safe for certain infections, the longer durations required for osteomyelitis increase the risk of adverse effects. Doxycycline should be considered only when no other active oral option is available, typically in older children, and with infectious diseases consultation. It is not appropriate for routine treatment. Many hospitals automatically consult orthopedics when children are admitted with osteomyelitis, and this is appropriate. Early orthopedic consultation should be viewed as team-based care, not failure of medical management. Consult orthopedics when MRI shows abscess or extensive disease, there is concern for septic arthritis, the child fails to improve within 48 to 72 hours, imaging suggests devitalized bone or growth plate involvement, there is a pathologic fracture, the patient is a neonate, or diagnostic bone sampling or operative drainage is being considered. Routine surgical debridement is not required for uncomplicated cases. Infectious diseases consultation is also often automatic and supported by guidelines. ID is particularly valuable for antibiotic selection, dosing, IV-to-oral transition, duration decisions, bacteremia management, adverse reactions, and salvage regimens. Even in straightforward cases, ID involvement often facilitates shorter IV courses and earlier oral transition. Osteomyelitis is generally not contagious, and clustering is uncommon for Staphylococcus aureus. Kingella kingae is the key exception. It colonizes the oropharynx of young children and spreads via close contact. Clusters of invasive Kingelladisease have been documented in daycare settings. Suspicion should be higher in children six to 36 months from the same daycare, with recent viral illness, mild systemic symptoms, refusal to bear weight, modest CRP elevation, and negative routine cultures unless PCR testing is used. Public health intervention is not typically required, but awareness is critical. There is no minimum required duration of IV therapy for uncomplicated acute hematogenous osteomyelitis. Transition to oral therapy should be based on clinical improvement plus CRP decline. Many children meet criteria within two to six days. Oral antibiotics must be dosed higher than standard outpatient regimens to ensure adequate bone penetration. Common regimens include high-dose cephalexin, clindamycin, or linezolid in select cases. The oral agent should mirror the IV agent that produced clinical improvement. Total duration is typically three to four weeks, and in many cases 15 to 20 days is sufficient. MRSA infections or complicated cases usually require four to six weeks. Early oral transition yields outcomes comparable to prolonged IV therapy with fewer complications. Most treatment-related complications occur during parenteral therapy, largely due to catheter-related issues. Take-home points: osteomyelitis in children is a clinical diagnosis supported by labs and MRI. Empiric antibiotics should be guided by age, illness severity, and local MRSA prevalence. Early transition to high-dose oral therapy is safe and effective when clinical response and CRP support it. Orthopedics and infectious diseases consultation improve care and reduce variation. FAST MRI is changing how we diagnose osteomyelitis. Daycare clustering is uncommon except with Kingella kingae. That's all for this episode. If there are other topics you'd like us to cover, let me know. If you have the time, leave a review on your favorite podcast platform. It helps more people find the show and learn from it. For PEM Currents, this has been Brad Sobolewski. See you next time.    

Moxifloxacin is a fourth-generation fluoroquinolone that works by inhibiting bacterial DNA gyrase and topoisomerase IV—two enzymes essential for DNA replication, repair, and transcription. By blocking both targets, it provides broad-spectrum activity against gram-positive, gram-negative, and atypical pathogens. Its enhanced gram-positive coverage, especially against Streptococcus pneumoniae, distinguishes it from earlier fluoroquinolones like ciprofloxacin. Pharmacokinetically, moxifloxacin has excellent oral bioavailability, meaning the PO and IV doses are essentially interchangeable. It distributes well into tissues like the lungs and sinuses, making it a frequent choice for respiratory infections. With a long half-life of about 12 hours, once-daily dosing is standard. Adverse effects are similar to the fluoroquinolone class, with concerns including tendonitis and tendon rupture, QT interval prolongation, CNS effects like confusion or agitation—particularly in older adults—and the risk of peripheral neuropathy. Moxifloxacin is especially notable for a higher propensity toward QT prolongation compared with some of its peers, making it important to avoid in patients with existing QT issues or those taking other QT-prolonging medications. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101

Episode 204: Adult Pneumococcal Vaccines in 2025.  Luz Perez (MSIV) presents all the available pneumococcal vaccines for adults. Dr. Arreaza guides the discussion about what to do with adults who have previously received pneumococcal vaccines. Written by Luz Perez, MSIV, Ross University School of Medicine. Comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Today we're answering a clinic classic: Which pneumococcal vaccine should my adult patient get—and when? This is an update of episode 90.Why pneumococcal vaccines matter?Pneumococcal vaccines prevent infections caused by the bacteria Streptococcus pneumonia. These bacteria can cause serious infections like pneumonia, meningitis, and bacteremia. In 2017, the CDC reports that there were more than 31,000 cases of pneumococcal infections and 3,500 deaths from invasive pneumococcal disease. Children are vaccinated in early childhood, before age 5, with PCV15 or PCV 20, at the age of 2, 4, 6 months and a last dose around 12-15 months. Why do we vaccinate adults?Adults are vaccinated because they're at higher risk of getting pneumococcal disease or of having worse outcomes if they do. Vaccines are important because they protect these at-risk patients and reduce the spread of infections among communities. What are the available vaccines? PCV vs PPSV.There are two pneumococcal vaccines used in practice: a polysaccharide vaccine (PPSV) and a conjugate vaccine (PCV). Both protect by targeting capsular polysaccharides from pneumococcal serotypes most often responsible for invasive disease. In simple terms, these vaccines target a part of the bacteria “coating” and create antibodies or proteins that protect the body when the strep enters the body. PPSV (polysaccharide): PPSV is made from purified pieces of the pneumococcal capsule or coating. The current vaccine PPSV23 (Pneumovax®) covers 23 serotypes (or strains) that were the leading cause of pneumococcal infections in the 1980s. PCV (conjugate): Pneumococcal conjugate vaccines (PCVs) take capsular polysaccharides from the bacterium and chemically link them to a carrier protein, which changes and strengthens the immune response. Current PCVs come in four versions: PCV13 (Prevnar 13)PCV15 (Vaxneuvance)PCV20 (Prevnar 20)PCV21 (Capvaxive) The number indicates the amount of pneumococcal capsule types covered by each vaccine. PCV21 was designed around adult disease patterns and covers many serotypes currently driving invasive disease in adults. However, it does not include serotype 4, but this serotype is covered by the PCV20 and PCV15.Who should be vaccinated? In 2024, the United States Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) updated their recommendations on Pneumococcal vaccinations for adults. Their recommendations are: Everyone 50 years or olderAdults age 19–49 with risks: chronic lung/liver disease, heart failure, diabetes; CSF leak or cochlear implant; immunocompromised states (e.g., HIV, hematologic malignancy, CKD/nephrotic syndrome); functional/anatomic asplenia.Patients with history of prior invasive pneumococcal disease: still vaccinate. What vaccine should be given for adults that have never received the Pneumococcal vaccine?For eligible adults with no prior pneumococcal vaccines, there are three choices:PCV21 oncePCV20 oncePCV15 now, followed by PPSV23 later, usually 1 year; 8 weeks if immunocompromised, CSF leak, or cochlear implant.PCV 20 or PCV21 seem more convenient. Once and done. If available, PCV21 is a great one-and-done pick for most adults because it's tailored to current adult serotypes.Serotype 4 caveat: If your patient is at higher risk for serotype 4 disease—think Navajo Nation, or folks in the Western US/Canada with substance use disorders or experiencing homelessness—choose PCV20 (or PCV15 followed by PPSV23 if PCV20 isn't available).What if the patient already received a Pneumococcal vaccine in the past?Plan depends on which vaccine they received and when.PPSV23 only: give PCV21 ≥1 year later (or PCV20 if serotype-4 risk or PCV21 unavailable).PCV10 or PCV13 only: give PCV21 (or PCV20 if PCV21 unavailable) ≥1 year later. If a PCV is not available, discuss PPSV23 now vs waiting until PCV is available.If patient receives PPSV23 now will need to return ≥1 year later to receive a PCV vaccine, and no more vaccines are needed after that.Is it safe to administer the Pneumococcal vaccine with other vaccines?Coadministration is fine with other non-pneumococcal vaccines, as long as we use different syringes and sites. Data support same-day administration of PPSV23 + influenza, and PCV20 with influenza or mRNA COVID-19 vaccines.Some patients are hesitant to receive vaccines, Are there side effects and contraindications to the vaccine?Local reactions are most common: pain/tenderness; swelling/induration (~20%); redness (~15%). Some people “baby” the arm for a couple of days. These typically resolve in 3–4 days; NSAIDs and warm compresses help.Systemic symptoms: fatigue, headache, myalgias/arthralgias, chills; fever ≥38°C is uncommon (

Subscribers can enjoy exclusive, extended conversations from this podcast. To subscribe, go to BumpInTheRoad.Substack.com   Ethan Pompeo  faced debilitating neurological symptoms at a young age. At just 13, he began experiencing motor tics, obsessive-compulsive disorder, and severe anxiety. By the time he was 17,  he was on over 40 different medications.   Ethan felt lost in a system that seemed more focused on prescribing medications than finding the root cause of his issues. He decided to take charge of his own health. Through extensive research, Ethan discovered PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), a condition that linked his neurological symptoms to a strep throat infection. Finally, he had an accurate diagnosis.  Part of Ethan's health plan was CBD, which he found to be a powerful anti-inflammatory. His experience led him to create Green Valley Nutrition, a company dedicated to providing high-quality CBD products for those seeking natural remedies for pain, anxiety, and sleep issues. Ethan's story is about taking charge of your health and your  life. It's about being open minded, curious and willing to step well outside the comfort zone of modern medicine to seek the healing that rings true for you.     What they're saying:   “This is a beautiful book about life, its imperfections, its challenges, and its joys. It is a book of hope and wisdom for all of us facing a bump in the road.” –Pragito Dove   “Pat has woven together beautiful stories of life setbacks that have been transformed into spiritual growth. This book is a gift and a must-read for souls experiencing pain and yearning for growth.”   –Gary Hensel   Learn more at   Follow Bump on: ➡️  ➡️  ➡️  ➡️  ➡️     

Hey Poison Friends!! I hope we are all staying well so far this (almost) Fall season. I know, the Autumnal Equinox won't be here until next month, but I am excited for Fall and spooky season and cooler weather. The one thing I do not like this time of year is the amount of viral and bacterial infections that seem to wage war on us all. One such bacterial agent is Streptococcus pyogenes or what you may hear called Group A Strep. This is the nasty that causes impetigo and strep throat (streptococcus pharyngitis) which can then lead to scarlet fever and rheumatic fever which can also lead to numerous complications like rheumatic heart disease and long term kidney dysfunction. All of that from strep throat or impetigo?? Yes, but fortunately we do not see these other complications as often thanks to antibiotics and preventative measures such as hand hygiene, isolation when contagious, and sanitation measures. It is still prevalent enough to cause a few thousand deaths here in America every year, however, and many more in countries who do not have good access to medical care and antibiotics. We are also discussing Invasive Group A Strep, because a strep infection can also lead to sepsis involving necrotizing fasciitis and toxic shock syndrome. Both of these complications are life threatening. We need to cover the demise of one of my all time favorite creators in this episode as well, Jim Henson. He died of TSS resulting from an untreated strep infection and, as sad as this was, his story needs to be told so that others don't. I won't spoil this episode any further, but I want to include the last message he had written to be given to his five children after his death.“First of all, don't feel bad that I'm gone. While I will miss spending time with each of you, I'm sure it will be an interesting time for me and I look forward to seeing all of you when you come over. To each of you I send my love. If on this side of life I'm able to watch over and help you out, know that I will. If I can't, I'm sure I can at least be waiting for you when you come over. This all may sound silly to you guys, but what the hell, I'm gone—and who can argue with me?Life is meant to be fun, and joyous, and fulfilling. May each of yours be that—having each of you as a child of mine has certainly been one of the good things in my life. Know that I've always loved each of you with an eternal, bottomless love. A love that has nothing to do with each other, for I feel my love for each of you is total and all encompassing. Please watch out for each other and love and forgive everybody. It's a good life, enjoy it.”Thank you to all of our listeners and supporters! Please feel free to leave a comment or send us a DM for any questions, suggestions, or just to say, "hi."Support us on Patreon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/thepoisonersalmanac⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Merch-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://poisonersalmanac.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow us on socials:The Poisoner's Almanac on IG-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/poisoners_almanac?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@thepoisonersalmanac-m5q?si=16JV_ZKhpGaLyM73⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Also, look for the Poisoner's Almanac TikTok- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@poisonersalmanacp?_t=ZT-8wdYQyXhKbm&_r=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adam-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@studiesshow?is_from_webapp=1&sender_device=pc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Becca-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@yobec0?is_from_webapp=1&sender_device=pc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

On this podcast, I cover ciprofloxacin pharmacology. Ciprofloxacin is one of the most widely recognized fluoroquinolone antibiotics and has been on the market for decades. Because of its broad utility, it often comes up in practice, but it also carries significant adverse effect concerns and boxed warnings that pharmacists and prescribers need to keep in mind. From a pharmacology standpoint, ciprofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for bacterial DNA replication, transcription, and repair. This action gives ciprofloxacin bactericidal activity against a variety of gram-negative organisms, including E. coli, Klebsiella, Enterobacter, and Pseudomonas aeruginosa. It also has some gram-positive activity, though it is generally not the best choice for strep infections. Ciprofloxacin comes in multiple dosage forms, including oral tablets, oral suspension, and intravenous formulations, which makes it flexible across care settings. I discuss the conversion of IV and PO formulations. Pharmacokinetics are important to consider. Ciprofloxacin is primarily renally eliminated, so dose adjustments are necessary in patients with impaired kidney function. Distribution into tissues is generally good, but it has limited activity in the lungs against Streptococcus pneumoniae, which is why it is not a first-line option for community-acquired pneumonia. Adverse effects are a major concern. The fluoroquinolone class carries multiple boxed warnings. Ciprofloxacin has been associated with tendon rupture, peripheral neuropathy, CNS effects such as agitation or seizures, and exacerbation of myasthenia gravis. More recent warnings include the risk for aortic aneurysm and hypoglycemia or hyperglycemia, particularly in older adults or those with comorbidities. On top of these boxed warnings, ciprofloxacin can also prolong the QT interval and cause GI upset. Drug interactions are another big factor in practice. Ciprofloxacin is a CYP1A2 inhibitor, which can raise levels of drugs like theophylline, tizanidine, and clozapine. It also interacts with polyvalent cations such as calcium, magnesium, iron, and aluminum, which can dramatically reduce its absorption—sometimes by more than 50%. This is a common reason for treatment failure if counseling isn't provided. From a dosing perspective, ciprofloxacin is usually given 250–750 mg orally twice daily or 400 mg IV every 8–12 hours depending on the indication and severity of infection. Renal dosing adjustments are needed as kidney function declines. In summary, ciprofloxacin is a powerful antibiotic when used appropriately. It remains an option for urinary tract infections, complicated intra-abdominal infections, and some cases of hospital-acquired pneumonia, but its use must be balanced with the potential for significant adverse effects and interactions. For pharmacists, educating patients on drug interactions, counseling about boxed warnings, and ensuring correct dosing in renal impairment are some of the most valuable interventions when ciprofloxacin shows up on a medication list.

Drs. Whitney Hartlage (@whithartlage11) and Sam Windham join Dr. Ryan Moenster to discuss updates in the diagnosis and management of community-acquire pneumonia. Hear from our guests on the role of rapid diagnostic tests such as multiplex PCR and urinary antigen tests in the inpatient and outpatient setting, considerations for initiating steroids and withholding macrolides, and when to use short antibiotic durations. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/. Visit our website! https://breakpoints-sidp.org/ References: Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. PMID: 31573350; PMCID: PMC6812437. Chaudhuri D, Nei AM, Rochwerg B, Balk RA, Asehnoune K, Cadena R, Carcillo JA, Correa R, Drover K, Esper AM, Gershengorn HB, Hammond NE, Jayaprakash N, Menon K, Nazer L, Pitre T, Qasim ZA, Russell JA, Santos AP, Sarwal A, Spencer-Segal J, Tilouche N, Annane D, Pastores SM. 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia. Crit Care Med. 2024 May 1;52(5):e219-e233. doi: 10.1097/CCM.0000000000006172. Epub 2024 Jan 19. PMID: 38240492. Odeyemi Y, Tekin A, Schanz C, Schreier D, Cole K, Gajic O, Barreto E. Comparative effectiveness of azithromycin versus doxycycline in hospitalized patients with community acquired pneumonia treated with beta-lactams: A multicenter matched cohort study. Clin Infect Dis. 2025 May 16:ciaf252. doi: 10.1093/cid/ciaf252. Epub ahead of print. PMID: 40378193. Butler AM, Nickel KB, Olsen MA, Sahrmann JM, Colvin R, Neuner E, O'Neil CA, Fraser VJ, Durkin MJ. Comparative safety of different antibiotic regimens for the treatment of outpatient community-acquired pneumonia among otherwise healthy adults. Clin Infect Dis. 2024 Oct 23:ciae519. doi: 10.1093/cid/ciae519. Epub ahead of print. PMID: 39442057; PMCID: PMC12355227. Furukawa Y, Luo Y, Funada S, Onishi A, Ostinelli E, Hamza T, Furukawa TA, Kataoka Y. Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. BMJ Open. 2023 Mar 22;13(3):e061023. doi: 10.1136/bmjopen-2022-061023. PMID: 36948555; PMCID: PMC10040075 Schober T, Wong K, DeLisle G, et al. Clinical outcomes of rapid respiratory virus testing in emergency departments. JAMA Intern Med. 2024;184(5):528-536. Clark T, Lindsley K, Wigmosta T, et al. Rapid multiplex PCR for respiratory viruses reduces time to result and improves clinical care: results of a systematic review and meta-analysis. J Infect. 2023;86(5):462-475. May L, Robbins EM, Canchola JA, Chugh K, Tran NK. A study to assess the impact of the cobas point-of-care RT-PCR assay (SARS-CoV-2 and Influenza A/B) on patient clinical management in the emergency department of the University of California at David Medical Center. J Clin Virol. 2023:168:105597. Cartuliares MB, Rosenvinge FS, Mogensen CB, Skovsted TA, Andersen SL, Østergaard C, et al. Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: a multicentre randomised controlled trial. PLoS Med. 2023;20:e1004314. doi: 10.1371/ journal.pmed.1004314. Vaughn VM, Dickson RP, Horowitz JK, Flanders SA. Community-acquired pneumonia: a review. JAMA. 2024;332(15):1282-1295. Davis MR, McCreary EK, Trzebucki AM. Things we do for no reason – ordering Streptococcus pneumoniae urinary antigen in patients with community-acquired pneumonia. Open Forum Infect Dis. 2024;11(3):ofae089. Centers for Disease Control and Prevention. Laboratory Testing for Legionella. Updated June 9, 2025. Accessed July 13, 2025. https://www.cdc.gov/legionella/php/laboratories/index.html. Jain S, Self WH, Wunderink RG. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427. Kamat IS, Ramachandram V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538-542. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single blinded intervention trial. Lancet. 2004;363:600–7. doi: 10.1016/S0140- 6736(04)15591-8. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302:1059–66. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalci- € tonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Datab System Rev. 2017;10(10):CD007498. doi: 10.1002/14651858. cd007498.pub2. Huang DT, Yealy DM, Filbin MR, Brown AM, Chang C-CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower Respiratory tract infection. New Engl J Med. 2018;379:236–49. doi: 10.1056/NEJMoa1802670. Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;389(19):1623-1634. doi:10.1056/NEJMoa2215145. Gupta AB, Flanders SA, Petty LA, et al. Inappropriate diagnosis of pneumonia among hospitalized adults. JAMA Intern Med. 2024;184(5):548-556. Jones BE, Chapman AB, Ying J, et al. Diagnostic Discordance, Uncertainty, and Treatment Ambiguity in Community-Acquired Pneumonia: A National Cohort Study of 115 U.S. Veterans Affairs Hospitals. Ann Intern Med. 2024;177(9):1179-1189. doi:10.7326/M23-2505. Hartlage W, Imlay H, Spivak ES. The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. Antimicrob Steward Healthc Epidemiol. 2024;4(1):e214. doi:10.1017/ash.2024.453. Dinh A, Barbier F, Bedos JP, et al. Update of guidelines for management of community acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF). Endorsed by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF); endorsed by the French Intensive Care Society (SRLF), the French Microbiology Society (SFM), the French Radiology Society (SFR), and the French Emergency Society (SFMU). Respir Med and Res. 2025. El Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355. doi:10.1136/bmj.332.7554.1355. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia: a randomized, non-inferiority trial. Lancet. 2021;397(10280):1195-1203.

Send us a textNew Matter host Emily Yamasaki, PhD, speaks with Vasumitra “Vasu” Rao, MS, PhD candidate–recipient of the 2025 SLAS Graduate Education Fellowship Grant–about his innovative research at the Jensen Lab (University of Michigan).Vasu's work focuses on AI-driven characterization of non-model oral bacteria (e.g., Streptococcus mutans), aiming to predict microbial growth dynamics and biofilm formation using neural ordinary differential equations (ODEs) and automated high-throughput experiments. His research bridges gaps in microbiology by studying under-explored organisms beyond traditional models, such as E. coli. Potential applications include understanding cavity formation, drug discovery, and pharmacodynamics modeling.He shares his unconventional path into AI/microbiology (inspired by chess and reinforcement learning), and discusses how the SLAS grant supports his exploratory research.About the SLAS Graduate Education Fellowship Grant:This SLAS grant facilitates educational opportunities for outstanding students pursuing graduate degrees related to life sciences R&D. This program helps to realize a fundamental tenet of SLAS's mission: to advance the fields of laboratory science and technology by nurturing the next generation of professional scientists. SLAS will award one grant (up to $50,000) per year, for a maximum of two years, to qualified educational institutions on behalf of deserving students enrolled in a graduate program at that institution.2026 application submissions are now being accepted!Learn MoreStay connected with SLASOnline at www.slas.orgFacebookTwitter @SLAS_OrgLinkedInInstagram @slas_orgYouTubeAbout SLASSLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building. For more information about SLAS, visit www.slas.org.SLAS2026 International Conference & Exhibition February 7-11, 2026 Boston, MA SLAS Europe 2026 Conference and Exhibition 19-21 May 2026 Vienna, Austria View the full events calendar

Send us a textSign up for my July Workshop: How to Calm Your Teen's Anxiety Without Triggering YoursCould your child's anxiety or tics be something more? Meet Ethan Pompeo, whose health journey led to answers—and a mission to help others.Ethan was misdiagnosed with Tourette's as a teen and put on over 40 medications before discovering the real root of his symptoms: PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus). In this powerful interview, Ethan shares his long road to healing, how CBD became a turning point, and why he now helps families find natural, effective relief through his company, Green Valley Nutrition.

Xylitol does it all—at least when it comes to fighting cavity-causing bacteria! In Part 2 of Irene's chat with Epic Dental's Donald and Monica Bailey, they dive into the science of how xylitol targets Streptococcus mutans while sparing good bacteria. The Baileys also discuss their commitment to education, product transparency, and making it easier for dental pros to help patients maintain oral health. Learn more & explore the research:

On episode #82 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 5/22 – 6/4/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Estimated Current and Future Congenital Rubella Syndrome Incidence with and Without Rubella Vaccine Introduction — 19 Countries, 2019–2055 (CDC: MMWR) HIV-Superinfection in Kidney Transplant Recipients with HIV who Received Organs from Donors with HIV (JID) Respiratory syncytial virus: an under-recognized healthcare-associated infection (Infection Control and Hospital Epidemiology) Bacterial Francisella tularensis Subspecies holarctica in Stranded Beluga Whales, Cook Inlet, Alaska, USA (CDC: Emerging Infectious Diseases) Long-term effects of azithromycin mass administration to reduce childhood mortality on Streptococcus pneumoniae antimicrobial resistance (LANCET: Infectious Diseases) Reducing inappropriate antibiotic use in febrile neutropenia in hematology patients through the implementation of an antibiotic de-escalation protocol (Infection Control and Hospital Epidemiology) Optimizing cefazolin dosing for central nervous system infections: insights from population pharmacokinetics and Monte Carlo simulations (Antimicrobial Agents and Chemotherapy) Fungal The Last of US Season 2 (YouTube) Histoplasma antigenuria prevalence in patients with advanced HIV disease in Côted'Ivoire (CID) Interferon-γ therapy in patients with refractory disseminated coccidioidomycosis(CID) Practical Guidance for Clinical Microbiology Laboratories: Antibody and antigen detection methods for dimorphic fungal infections (Clinical Microbiology Reviews) Parasitic Notes from the Field: Primary Amebic Meningoencephalitis Associated with Nasal Irrigation Using Water from a Recreational Vehicle — Texas, 2024 (CDC: MMWR) Further Evidence for Plausible Transmission of Fishborne Trematodiases in the United States: Game Fish Carry Human-Infectious Trematodes and Are Eaten Raw (JID) Miscellaneous A pilot study of coughing into the shirt to disrupt respiratory pathogen transmission (International Journal Of Emergency Medicine) Applying new compound to bed nets targets malaria parasites, not mosquitoes (CIDRAP) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Two new studies from the Society for Investigative Dermatology (SID) conference reveal how Staph bacteria use clever strategies to disarm the skin's barrier maintenance function and work with other bacteria to amplify inflammation. Join us for an interview with Dr. Nathan Archer and Dr. Laine Feller from John Hopkins School of Medicine who explain how Staph aureus bacteria uses its superantigen superpower to hinder lipid production ... and more new research from this year's SID meeting.

Plaque and tartar are biofilms, which can be described as a protective shield against the immune system in your mouth. Biofilms are produced by a microbe called Streptococcus mutans, which also causes cavities. Surprisingly, this microbe has been found in other parts of the body, including the valves of the heart and the plaque in your arteries. Sugar consumption is one of the leading causes of tartar, but consuming sugar with starch is even worse! This can form a glue that sticks to your teeth. You must stop eating starch and sugar to prevent plaque and tartar from forming. To make a natural toothpaste that can effectively remove plaque, combine the following:•1/2 teaspoon 3% hydrogen peroxide, food-grade•1/2 teaspoon baking soda•3 drops of clove oil •1/2 teaspoon microcrystalline hydroxyapatite Combine 3 teaspoons of water with this mixture and brush your teeth with the mixture once daily. Hydrogen peroxide helps break down biofilms and whiten teeth. Baking soda has mild abrasive properties to clean teeth and alkalize the mouth. Clove oil is the best essential oil for oral health. It breaks down tartar and can even help decrease oral pain. Microcrystalline hydroxyapatite can enter the small crevices of the teeth and remineralize the bone tissue. It also prevents acid from breaking down the tooth. You can also chew certain types of gum that can help repopulate the friendly bacteria in the mouth and protect you against the formation of biofilms. Friendly bacteria in your mouth can help prevent tartar, bad breath, and cavities. Grass-fed butter is one of the healthiest foods for teeth. It's a potent source of vitamin K2, which pushes the calcium in your body into your bones. Butter also contains vitamin A, which strengthens your enamel, and butyrate, which supports the brain and colon.

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the USF Morsani College of Medicine, Division of Infectious Diseases, presents a case-based discussion of gram positive organisms producing disease in humans. Infections discussed include Staphylococcus aureus, Coagulase negative Staphylococcus, Pneumococcus, Streptococcus spp., Enterococcus, Corynebacterium, Bacillus, and Erysipelothrix. Associated clinical syndromes are also discussed.

In this episode of the EMJ Podcast, Jonathan Sackier sits down with Jose Alexander, Clinical Microbiologist and Director of Microbiology at AdventHealth Orlando, to explore the cutting edge of infectious disease diagnostics. From next-generation sequencing to rapid tests for brain-eating amoeba, Alexander shares insights into the latest innovations shaping the field, the fight against antimicrobial resistance, and the future of microbiology diagnostics. Timestamps: 00:00 – Introduction 03:55 – Alexander's introduction to microbiology 05:42 – Developing a rapid test for a brain-eating amoeba 09:40 – Where is this amoeba found? 12:13 – Next-generation sequencing in infectious disease 14:36 – Streptococcus pneumoniae serotype/genotype service 17:06 – Vaccine hesitancy 19:03 – Antimicrobial resistance 22:02 – The discovery of a novel variant of Klebsiella pneumoniae 24:32 – The clinical use of bacteriophages 27:01 – The future of the field 28:41 – Alexander's three wishes for healthcare

On 24th March 1603, Queen Elizabeth I passed away at the age of 69—but what exactly caused her death? Despite being one of history's most documented monarchs, the exact cause of Elizabeth's death remains a mystery. Historians and medical experts have proposed various theories, including: - A deadly tooth abscess—Could an infection have turned septic? - Lead poisoning—Did her makeup slowly poison her? - Pneumonia—She suffered breathing difficulties and fever. - Streptococcus infection—Could an untreated illness have taken her life? - Psychogenic death—Did she literally give up on life?   Elizabeth's final weeks were filled with grief, exhaustion, and refusal of medical treatment. Was she suffering from a fatal illness, or did loneliness and heartbreak cause her slow decline? Join me as I explore the mysteries surrounding Elizabeth's final days and discuss the most convincing theories.   What do you think killed Elizabeth I?   #ElizabethI #TudorHistory #TheVirginQueen #Mystery #TudorDynasty #HistoryLovers #RoyalHistory #16thCentury #WhatKilledElizabethI #BritishHistory #TudorMysteries

Story at-a-glance Rising incidence of early-onset colorectal cancer is linked to changes in the gut microbiome, with specific bacterial strains producing mutagenic chemicals that contribute to cancer risk Global studies are underway to identify mutational signatures associated with gut bacteria, highlighting the significant role of dysbiosis in colorectal carcinogenesis Understanding the influence of gut bacteria on cancer development could lead to innovative therapeutic strategies, offering new avenues for prevention and treatment Research has identified a subtype of E. coli producing colibactin, a mutagen associated with cancer, suggesting that early exposure increases the risk of developing cancer at a younger age Dysbiosis, characterized by an imbalance in gut microbiota, is linked to colorectal cancer through mechanisms like genotoxicity, inflammation and oxidative stress, with specific bacteria such as Streptococcus bovis and Fusobacterium spp. playing a central role

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

The spread of high-risk human and animal diseases across borders in the last five years has clearly demonstrated that the best-laid plans can go wrong when it comes to infectious disease control and prevention. In fact, North American and European countries proved decades ago that swine diseases like ASF and classical swine fever can be eradicated through effective government policies, even without ideal vaccines. However, the world has since changed.Joining our Ann Hess to discuss this topic and more from the PRRS Symposium in Chicago is Dr. Jishu Shi of Kansas State University. Dr. Jishu Shi's research team develops vaccine adjuvants, novel diagnostic assays and vaccines for swine infectious diseases. Specifically, his team focuses research on African swine fever (ASF), Streptococcus suis, swine influenza virus (SIV), classical swine fever (CSF), porcine reproductive and respiratory syndrome (PRRS), and other emerging infectious diseases of swine.This episode of Feedstuffs in Focus is sponsored by United Animal Health, a leader in animal health and nutrition. You can learn more about United Animal Health and how they are working to advance animal science worldwide by visiting the website at UnitedANH.com

Send us a textOn this episode of the CMAJ Podcast, Dr. Mojola Omole and Dr. Blair Bigham discuss necrotizing fasciitis, a diagnosis that can strike fear into the hearts of clinicians due to its rapid progression and devastating consequences. The discussion builds on insights from the CMAJ practice article, “Necrotizing soft tissue infections caused by invasive group A Streptococcus,” co-authored by Dr. Saswata Deb and Dr. Stephanie Mason.Dr. Deb, an emergency physician and clinician scientist at Sunnybrook Health Sciences Centre in Toronto, outlines the key clinical signs of necrotizing fasciitis, including pain out of proportion to physical findings and rapid hemodynamic deterioration. He emphasizes the importance of considering NSTI in the differential diagnosis for cellulitis and the need for prompt surgical consultation when red flags arise. Crucially, Dr. Deb explains that no imaging or laboratory tests can definitively rule in or rule out the diagnosis—only surgical exploration can confirm it.Dr. Mason, a burn and general surgeon at Sunnybrook's Ross Tilley Burn Centre, provides a surgeon's perspective on managing these infections. She addresses common missteps in diagnosis, the need for aggressive surgical debridement, and the role of multidisciplinary care in saving patients' lives. She also discusses how surgeons can overcome their fear of creating extensive wounds, reassuring listeners that reconstruction is possible once the patient is stabilized.Together, the guests and hosts explore practical solutions to reduce delays in care, including the potential for institutional protocols—possibly a "code nec fasc"—to streamline decision-making and improve outcomes.For more information from our sponsor, go to md.ca/tax. Join us as we explore medical solutions that address the urgent need to change healthcare. Reach out to us about this or any episode you hear. Or tell us about something you'd like to hear on the leading Canadian medical podcast.You can find Blair and Mojola on X @BlairBigham and @DrmojolaomoleX (in English): @CMAJ X (en français): @JAMC FacebookInstagram: @CMAJ.ca The CMAJ Podcast is produced by PodCraft Productions

In this episode, you'll get to explore the fascinating connection between oral health and overall wellness with guests Cass Nelson-Dooley and Katherine Dahl. Cass explains how everyday habits, like using antimicrobial mouthwash, can disrupt beneficial bacteria and impact cardiovascular health, while Catherine shares her journey of overcoming gut and oral health challenges to founding SuperTeeth, a company focused on oral microbiome health. We’ll also discuss the oral microbiome's role in systemic health, the benefits of dental probiotics like Streptococcus salivarius M18, the debate between fluoride and hydroxyapatite in toothpaste, and much more! GetSuperTeeth.comIG - @getsuperteethUse code BENGREENFIELD to get 20% off sitewide If you've ever wondered about the smarter choices for your oral care routine, the role of essential oils, or why your dentist might be interested in your overall health, you won't want to miss this episode. Full Show Notes: bengreenfieldlife.com/superteethpodcast Episode Sponsors: Organifi Green Juice: Go to organifi.com/Ben for 20% off! Analemma: To experience the science-backed power of coherent water for yourself, visit analemma-water.com and use code BENG for 10% off! LVLUP Health: Head over to lvluphealth.com/BGL for a special discount on their game-changing range of products. Force of Nature: Unlock 20% off your order at Force of Nature! Use code BEN at checkout for premium, responsibly sourced meats. Minimum $189 purchase required. Shop now at forceofnature.com/discount/BEN. Just Thrive: For a limited time, you can save 20% off a 90 day bottle of Just Thrive Probiotic and Just Calm at justthrivehealth.com/ben with promo code: BEN That’s like getting a month for FREE! Take control today with Just Thrive!See omnystudio.com/listener for privacy information.

I've touched on the topic of endotoxemia in past episodes of the Defiant Health podcast. In this episode, let's dive deeper into this topic that is absolutely crucial to understanding and managing SO many aspects of health, from subduing anxiety and panic, to depressive, to joint pain and skin rashes, to gastrointestinal conditions, even weight management. What is endotoxemia? Fecal microbes, so-called Gram-negative species because of the way these microbes take up stain for examination under a microscope, species such as E. coli and Salmonella, have something called lipopolysaccharide endotoxin in their cells walls. Other species, so-called Gram positive species such as Enterococcus, Staphylococcus, and Streptococcus, that stain in a different manner, have something called lipoteichoic acid in their cell walls. When these microbes die, both Gram-negative and Gram-positive, these toxic factors are released into the intestines. If these fecal microbes are confined to the colon, where they belong, a section of GI tract adapted to their presence, the entry of these toxic components are limited and current evidence is unclear in how importat this process is. The real trouble occurs, however, when fecal microbes have invaded the 24-feet of small intestine, a process we label small intetinal bacterial overgrowth, or SIBO, because the small intestine—the stomach, duodenum, jejunum, and ileum are not well-adapted to the invasion of fecal species. Here, they die, release their toxic components, which then enter the bloodstream, the process labeled endotoxemia. People with SIBO therefore have high blood levels, typically 200-400% higher, levels of endotoxin. This is how microbes in the GI Tract export their effects to all other parts of the body. So let's discuss this process and how you can take control over it to be be better able to take control over your emotions, mood, sleep, energy, weight, and numerous other aspects of health. _______________________________________________________________________________For BiotiQuest probiotics including Sugar Shift, go here.A 15% discount is available for Defiant Health podcast listeners by entering discount code UNDOC15 (case-sensitive) at checkout.*_________________________________________________________________________________Get your 15% Paleovalley discount on fermented grass-fed beef sticks, Bone Broth Collagen, low-carb snack bars and other high-quality organic foods here.* For 12% off every order of grass-fed and pasture-raised meats from Wild Pastures, go here._____________________________________________________________________________MyReuSupport the showBooks: Super Gut: The 4-Week Plan to Reprogram Your Microbiome, Restore Health, and Lose Weight Wheat Belly: Lose the Wheat, Lose the Weight and Find Your Path Back to Health; revised & expanded ed

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Streptococcus pneumoniae⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Microbiology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Streptococcus pyogenes (Group A Streptococci)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Microbiology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

GDP Script/ Top Stories for December 6th  Publish Date: December 6th    From the BG AD Group Studio Welcome to the Gwinnett Daily Post Podcast.  Today is Friday, December 6th and Happy Birthday to REM's Peter Buck.  ***12.06.24 - BIRTHDAY – PETER BUCK***  I'm Keith Ippolito and here are your top stories presented by Gwinnett KIA Mall of Georgia.  Two Arrested In Gwinnett Road Rage Shooting  Gwinnett Animal Shelter Closed After Illness Outbreak  Buford to host Holiday Festival and Parade on Saturday  All of this and more is coming up on the Gwinnett Daily Post podcast, and if you are looking for community news, we encourage you to listen daily and subscribe!  Break 1: 07.14.22 KIA MOG    STORY 1: Two Arrested In Gwinnett Road Rage Shooting  Two Riverdale residents, Paola Nicole Cruz Pena, 21, and David Jesus Ravelo Cedeno, 25, are facing charges after a road rage incident on Nov. 25 escalated into a shooting in a Peachtree Corners parking lot. The altercation began with a dispute between two vehicles, resulting in Cedeno shooting one individual during a physical confrontation. Police apprehended the suspects in Riverdale. Pena faces charges including aggravated assault and tampering with evidence, while Cedeno is charged with multiple offenses, including aggravated assault, firearm possession during a crime, and reckless conduct. Both are held in Gwinnett County Jail as police continue to investigate.  STORY 2:   Gwinnett Animal Shelter Closed After Illness Outbreak  The Bill Atkinson Animal Welfare Center in Gwinnett County is closed until Dec. 17 following an outbreak of Streptococcus zooepidemicus, which caused the deaths of three dogs. Strep Zoo, a bacterial infection, can cause severe respiratory distress, nasal discharge, and rapid health decline in dogs, potentially leading to death without timely antibiotic treatment. The center stopped adoptions and is collaborating with the Georgia Department of Agriculture to prevent further spread. Pet owners are advised to watch for symptoms and seek immediate veterinary care if needed. The shelter remains open for pet reclaims and intake of sick or aggressive animals.  STORY 3:  Buford to host Holiday Festival and Parade on Saturday  The Buford Business Alliance is hosting its annual Buford Holiday Festival and Parade on Saturday along Buford's Historic Main Street. The parade, featuring over 50 entries including the Buford Band of Wolves and Santa in a vintage red truck, starts at 9 a.m. and ends at the festival grounds at 301 East Main Street. The festival runs from 10 a.m. to 4 p.m. and includes holiday shopping, food trucks, performances, and a free Kids' Zone with bounce houses, a balloon artist, and caricature drawings. Guests can also enjoy free photos with Santa. Proceeds from the event support local nonprofit organizations, school groups, and scholarships for Buford High School seniors.    We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info.  We'll be right back    Break 2: 08.05.24 OBITS_FINAL    STORY 4: Attempted Murder Suspect From South Carolina Arrested In Gwinnett County  A 20-year-old man, Emmanuel Williams, was arrested in Gwinnett County for shooting and injuring two adults and a 1-year-old child in Seneca, S.C. Wanted for three counts of attempted murder, Williams was located using Flock cameras after being linked to a black SUV in the area. When police attempted a traffic stop, Williams fled, leading to an 80 mph chase. Officers performed a PIT maneuver near Duluth Highway, stopping the vehicle and arresting him. Williams faces charges including felony fleeing, reckless driving, driving on a suspended license, and more. He was checked for injuries before being booked into the Gwinnett County Jail.  STORY 5:  Gwinnett Police Remind Residents To Take Precautions After Coyote Sightings  Gwinnett County police are advising residents to stay cautious following multiple coyote sightings in the area. To ensure safety, they recommend removing food sources like pet food and birdseed from yards, keeping small pets indoors or supervised when outside, and always leashing dogs. Residents are encouraged to contact Gwinnett Animal Welfare at 770-339-3200 for concerns or unusual coyote activity. Officials noted that while coyotes are common, attacks on humans are rare, with most reports involving sightings.     Break 3:    STORY 6:  Ossoff grills postmaster general over continuing delays in mail delivery  U.S. Sen. Jon Ossoff criticized Postmaster General Louis DeJoy for failing to meet his pledge to restore on-time mail delivery in Georgia, which remains at 75%. The delays began after a new mail distribution center in Palmetto opened last year, with issues arising from a postal restructuring plan aimed at financial self-sufficiency. DeJoy admitted to ongoing challenges, despite promising improvements within 60 days. Ossoff highlighted the severe impacts on seniors awaiting prescriptions, small businesses, and timely delivery of critical notices. DeJoy defended the three-day target for mail delivery, while Ossoff urged for better performance.    STORY 7:  Brookwood Football Parts Ways with Head Coach Philip Jones  Brookwood High School has parted ways with head football coach Philip Jones after 10 seasons. Jones, an alum and former team captain of the 1996 state championship team, led the Broncos to the playoffs eight times, including a Final Four appearance in 2017. His deep ties to the program include playing and coaching under Brookwood legends and continuing his father's legacy as a longtime coach. Despite dealing with health struggles this past season, Jones' impact is widely recognized. The school will now start a nationwide search for a new coach to build on Brookwood's proud traditions and history of success.    Break 4: Ingles Markets 9    Signoff –   Thanks again for hanging out with us on today's Gwinnett Daily Post Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.gwinnettdailypost.com  Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts.  Produced by the BG Podcast Network     Show Sponsors:  www.ingles-markets.com    www.wagesfuneralhome.com   www.kiamallofga.com      #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversations   See omnystudio.com/listener for privacy information.

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Streptococcus bovis/gallolyticus ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Microbiology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

On episode #66 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 10/8 – 10/23/24. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Prevalence of Human Papillomavirus (HPV) and HPV Type Distribution in Penile Samples in Young Men in Denmark: Results 10 Years After Implementation of a Girls-Only HPV Vaccination Program (JID) Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America (CID) Bacterial Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation (LANCET: Infectious Diseases) Time to turn off the toxins: adjuvant suppression of group A streptococcus (LANCET: Infectious Diseases) Comparing rates of recurrent infection for first occurrence of Clostridioides difficile between tapered oral vancomycin and standard vancomycin: a retrospective, propensity matched cohort study(Infection Control and Hospital Epidemiology) Evaluation of primary oral vancomycin prophylaxis against C. difficile infection during autologous stem cell transplantation (OFID) Oral Vancomycin to Prevent C. difficile in Stem Cell Transplant Recipients: The last frontier in antimicrobial prophylaxis (OFID) First Report of a Fatal Septicemia Case Caused by Vibrio metoecus: A Comprehensive Functional and Genomic Study (JID) Fungal The Last of US Season 2 (YouTube) A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group(PLoS Neglected Tropical Diseases) Epidemiological and clinical features of a large blastomycosis outbreak at a paper mill in Michigan (CID) Do morphogenetic switching and intraspecies variation enhance virulence of Candida auris? (PLoS Pathogens) Parasitic Beyond Human Babesiosis: Prevalence and Association of Babesia Coinfection with Mortality in the United States, 2015–2022: A Retrospective Cohort Study (OFID) New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine (LANCET: Infectious Diseases) Miscellaneous Social and Environmental Benefitsof Pediatric Infectious Disease Telemedicine (Journal of the Pediatric Infectious Diseases Society) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Drs. Cesar Arias (@SuperBugDoc) and Katie Barber join Dr. Julie Ann Justo (@julie_justo) to discuss what is hot-off-the-presses for gram-positive bacterial infections and it's a total party vibe! They review the latest news for recent and ongoing clinical trials (DOTS, DISRUPT, and SNAP trials), discuss hope for novel clinical tests of the cefazolin inoculum effect in staphylococci, and explore the fascinating changes in virulence and potential therapeutic options for the most challenging enterococci. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References Climate Change and Antimicrobial Resistance. Editors in Conversation Podcast. American Society for Microbiology. Oct 2023. Is More Better? The Role of Combination Therapy for MRSA. Breakpoints Podcast Episode #30. Society of Infectious Diseases Pharmacists. Turner NA, et al. DOTS: Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia. ESCMID Global 2024. April 2024. NCT04775953. Real-world dalbavancin observational cohort: Rebold N, et al. Infect Dis Ther. 2024 Mar;13(3):565-579. doi: 10.1007/s40121-024-00933-2. PMID: 38427289. Exebacase DISRUPT trial : Fowler VG Jr, et al. Clin Infect Dis. 2024 Jun 14;78(6):1473-1481. doi: 10.1093/cid/ciae043. PMID: 38297916. @snap_trial tweet of Breaking News. Aug 2024. Investigator Resources for the SNAP trial. Sept 2024: https://www.snaptrial.com.au/for-investigators#interim Cefazolin inoculum effect on mortality in MSSA bacteremia : Miller WR, et al. Open Forum Infect Dis. 2018 May 23;5(6):ofy123. doi: 10.1093/ofid/ofy123. PMID: 29977970. Prevalence of cefazolin inoculum effect in MSSA and modified rapid nitrocefin test for detection: Carvajal LP, et al. Antimicrob Agents Chemother. 2024 Sep 30:e0089824. doi: 10.1128/aac.00898-24. PMID: 39345182. LiaX as surrogate for cell envelope stress in Enterococus faecium: Axell-House DB, et al. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0106923. doi: 10.1128/aac.01069-23. PMID: 38289081. Shorter is better for uncomplicated streptococcal bacteremia: Clutter DS, et al. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0022024. doi: 10.1128/aac.00220-24. PMID: 38975753. Short vs. long antibiotic duration in Streptococcus pneumoniae bacteremia: Crotty M, et al. Open Forum Infect Dis. 2024 Aug 30;11(9):ofae478. doi: 10.1093/ofid/ofae478. PMID: 39257675. This podcast is powered by Pinecast.

We are back again and this time addressing a question from a parent who wonders, "Do kids get sick more often in the back-to-school season and what can I do to keep my kids healthy?”  The short answer is “yes”.  It IS common for kids to get more frequent infections anytime they are around other people. Hand hygiene, social distancing, vaccines on top of a healthy foundation of adequate rest, good nutrition, movement are your best defenses. Viruses certainly predominate and can be recognized by general symptoms of fever, runny nose, cough, muscle aches, headaches, tummy aches and sore throat. A sore throat is a feature of VIRAL illness but what about strep throat? Strep throat is a BACTERIAL infection in the back of the throat (the pharynx) caused by Streptococcus pyogenes (also known as Group A strep). Pediatricians start to think about a bacterial infection when it is seen in isolation-a sore throat only or maybe with a headache or tummy ache but WITHOUT the more commonly recognized URI symptoms like runny nose and cough. When your doctor is concerned for strep throat, an easy throat swab done in the office with or without a bacterial culture is all that is needed to confirm or refute the diagnosis of strep throat. We treat strep throat with antibiotics (usually amoxicillin) to treat the infection but more importantly, to reduce the likelihood of post-strep sequelae such as rheumatic heart disease and post-streptococcal kidney disease.Is my kid getting sick too often? Check out Episode 5: House calls: “My child is always sick.” Frequency of colds and when to think it might be something else. 

On episode #63 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 8/29/24 – 9/13/24. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach (OFID) A New Orthonairovirus Associated with Human Febrile Illness (NEJM) Farmed fur animals harbour viruses with zoonotic spillover potential(Nature) A Cross-Sectional Evaluation of the Virtual Outpatient Management of People With Mpox (OFID) A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy (Transplant Infectious Disease) A Decade of Chronic Norovirus Infection Surveillance at the NIH Clinical Research Center: Clinical Characteristics, Molecular Epidemiology, and Replication (JID) Bacterial FDA clears newLyme disease test (CIDRAP) Lyme ImmunoBlot Receives FDA Clearance(Accesswire) The Utilization Of Echocardiography In Children With Staphylococcus aureus Bacteremia (Journal of Pediatric Infectious Diseases Society) Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia: is shorter truly better?(BMC Infectious Diseases) Short Versus Long Antibiotic Duration in Streptococcus pneumoniae Bacteremia (OFID) FDA Marketing Authorization Enables Increased Access to First Step of Syphilis Diagnosis FDA) Clinical impact of pleural fluid Streptococcus pneumoniae PCR testing in children with complicated pneumonia (CID) Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia: is shorter truly better? (BMC Infectious Diseases) Short Versus Long Antibiotic Duration in Streptococcus pneumoniae Bacteremia (OFID) Fungal The Last of US Season 2 (YouTube) Incidence and risk factors for invasive fungal infections in patients initiating TNF-alpha inhibitors for inflammatory bowel disease and rheumatoid arthritis (CID) Parasitic Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2 in mice(Science Translational Medicine) Miscellaneous Successful Treatment of Refractory Cutaneous Protothecosis With MAT2203, an Oral Lipid Nanocrystal Formulation of Amphotericin B (OFID) The Impact of Infectious Diseases Scholarly Mentorship on Subsequent Infectious Disease Fellowship Application (CID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

On episode #62 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 8/15/24 – 8/28/24. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Clinician Specialty and HIV PrEP Prescription Reversals and abandonments (JAMA Network: JAMA Internal Medicine) The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens (JIAS Journal of the International AIDS Society) Dexamethasone in adults with viral meningitis (CMI Clinical Microbiology and Infection) Oropouche Virus Disease Among U.S. Travelers — United States, 2024 (MMWR) Oropouche fever, the mysterious threat (LANCET: Infectious Diseases) Bacterial High rates of Non-susceptibility to common oral antibiotics in Streptococcus pneumoniae clinical isolates (OFID) New York State Department of Health Directs Providers to Discontinue Use of Ciprofloxacin to Prevent Meningococcal Disease Due to Increasing Antimicrobial Resistance (NY State: Department of Health) Tularemia Associated with Harbor Seal Necropsy — Kitsap County, Washington, October 2023 (MMWR) FDA Marketing Authorization Enables Increased Access to First Step of Syphilis Diagnosis (FDA) Clinical impact of pleural fluid Streptococcus pneumoniae PCR testing in children with complicated pneumonia (CID) The Role of the Gut, Urine and Vaginal Microbiome on the Pathogenesis of Urinary Tract Infection (OFID) Fungal The Last of US Season 2 (YouTube) Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan (LANCET Infectious disease) Parasitic Usefulness of real-time PCR for urogenital schistosomiasis in preschool children in Angola (PLoS Neglected Tropical Diseases) Helminth infection driven gastrointestinal hypermotility alterations in smooth muscle instead of enteric neurons (PLoS Pathogens) Die-off reaction of Demodex mites after treating demodicosis with oral ivermectin (JAAD case reports) Miscellaneous Prevalence of carbapenem-resistant gram negative bacteria among neonates suspected for sepsis in Africa (BMC Infectious Diseases) New era of targeted clinical guidelines: IDSA (CID) Defining the landscape of educational experiences in transplant infectious diseases (OFID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Haemorrhage, hypertensive disorders, and sepsis are responsible for more than half of maternal deaths worldwide. Further, it is estimated that for every death, there are 50 pregnant people with life-threatening morbidity from sepsis. Heartbreakingly, the incidence of puerperal sepsis has risen over the last decade, in some cases doubling, with increasing rates of severe sepsis contributing to mortality. Underlying this trend is increasing virulence of group A streptococcal (GAS) infection. This is suspected to be due to the predominance of emm1 and emm28 genotypes, which have higher associations with mortality, as well as increasing maternal risk factors for infection such as obesity and DM. PLUS, certain GAS antibiotic resistance is on the rise. Group A streptococcus infection remains an important contributor to pregnancy and puerperal morbidity and mortality. Early recognition, diagnosis and aggressive management are Important for favorable outcomes given the serious risk of sepsis and streptococcal toxic shock syndrome. In this episode, we will highlight this alarming rise of Group A strep in the peripartum period including the most recent 2021 International Society for Infectious Disease in Obstetrics and Gynecology (ISIDOG) guidelines regarding GAS in pregnancy. Listen in for details.

Greeny talks to Dan Graziano about the ever-changing odds for the #2 overall pick and if the Commanders should take Jayden Daniels even if it's not his preference to be in DC. We play Sneaky Hembo Trivia, debate how crucial it is for Joel Embiid to play in tonight's Game 2 against the Knicks, and get a worrying health update on another Sixers player. An old colleague has called Greeny out for engaging in too much hyperbole...no idea where he got that idea! We wrap up the hour discussing if Tom Thibodeau should've been a finalist for Coach of the Year. Learn more about your ad choices. Visit megaphone.fm/adchoices